Illinois-Based Akorn, Inc. Eyes $2 Billion UCB SA Unit In Potential Tax Inversion Deal

(Reuters) - U.S. specialty drugmaker Akorn Inc (AKRX.O) is exploring a bid for Belgian drugmaker UCB SA's (UCB.BR) U.S. subsidiary, a deal that would allow the company to move its tax domicile overseas in a practice known as inversion, according to people familiar with the matter.

UCB is looking to sell its U.S. specialty generics subsidiary, Kremers Urban Pharmaceuticals Inc, in a deal that could fetch as much as $2 billion, Reuters reported last month.

Akorn, an Illinois-based maker of specialty pharmaceuticals including opthalmic drugs, is among a small number of drugmakers that are looking at buying the business, people familiar with the matter said, asking not to be named because the matter is not public.

Help employers find you! Check out all the jobs and post your resume.